• Regulator-approved, globally deployed Felix sperm selection system generating rapidly growing recurring revenues
• Commercial rollout active across multiple regions: Europe, MENA, Japan and Australia
• Transition from early-stage commercialisation to scaling global revenues

Memphasys Limited (ASX: MEM) has released an updated investor presentation providing a comprehensive update on the company's progress as it transitions from early-stage commercialisation to scaling global revenues for its Felix sperm selection system. The presentation covers new and expanded information for investors, including updated revenue disclosures and recent multi-market sales performance, additional detail on recurring revenue dynamics driven by cartridge usage, enhanced disclosure on unit economics and target pricing and cost of goods sold, further clarity on gross margin potential and operating leverage, and expanded detail on commercial agreements and contracted revenue pathways. The company has achieved a commercial inflection point, with revenue now being generated across multiple jurisdictions, including a step-change in the March quarter driven by contributions from Italy and Qatar. The updated commercial strategy is now delivering measurable revenue outcomes, with the company focused on a go-direct IVF clinic engagement model, high-value, regulator-ready markets, and conversion from evaluation to commercial supply agreements. The presentation also highlights the global fertility market opportunity, the advantages of the Felix system over conventional sperm preparation methods, and the regulatory approvals now driving commercial growth. The company has secured commercial agreements in key markets, including Europe, the Middle East and North Africa, Japan, and India, with repeat ordering behavior confirming adoption and a scalable recurring revenue model.

The company is targeting a cartridge price of $80-$150 with a cost of goods sold of less than $40, resulting in a gross margin potential of over 60%. The company expects to generate annual revenue of $100,000 to $300,000 per clinic, with revenue growth driven by utilization and not just new customer acquisition.

Over the next 6 months, Memphasys expects to see continued scaling of its business in Europe, the Middle East, and Asia-Pacific, the commercialization of its product in Australia, the completion of regulatory approval in India, and further improvements in its cost of goods sold.